Skip to main content

Table 2 Patients’ basic demographic variables and treatments

From: Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

 

Survivors

Non-survivors

Patient ID

2

3

4

8

10

11

1*

5

6

7

9

Hospital

1

1

2

1

2

2

1

2

2

1

2

Cell type**

UC-MSC

UC-MSC

UC-MSC

PL-MSC

PL-MSC

PL-MSC

UC-MSC

UC-MSC

UC-MSC

PL-MSC

PL-MSC

Age (years)***

60–65

55–60

65–70

60–65

40–45

45–50

65–70

50–55

55–60

35–40

60–65

Sex (1/2)***

2

2

1

1

1

1

2

1

1

1

1

Weight (kg)

80

69

60

95

85

103

80

80

87

85

94

Underlying disease

HTN, DM

–

CLL

CMP, DM

–

HTN

HTN, DM

–

–

–

DM

Treatment protocol

HCQ, Kaletra

HCQ, Kaletra

HCQ, Kaletra, Azithromycin, IVIG, Ribavarin

HCQ, Kaletra

Meropenem, Vancomycin, IVIG,

Favipiravir

Kaletra, Meropenem, Vancomycin, Tamiflu, IVIG, Favipiravir

HCQ, Kaletra

HCQ, Kaletra, Azithromycin, IVIG, + ECMO

Kaletra, Ribavirin, Vancomycin, Imiper, IVIG

HCQ, Kaletra

Kaletra, Meropenem, Colistin, IVIG

qRT-PCR

+

+

+

+

+

+

−

+

+

+

+

  1. HCQ hydroxychloroquine, HTN hypertension, DM diabetes mellitus, IVIG intravenous immunoglobulin, ECMO extracorporeal membrane oxygenation, qRT-PCR quantitative reverse transcription-polymerase chain reaction, CMP cardiomyopathy, CLL chronic lymphocytic leukemia, UC-MSC umbilical cord mesenchymal stem cells, PL-MSC placental MSC
  2. *qRT-PCR in this patient was initially negative but history, clinical presentation, and radiography of the patient were indicative of COVID-19 infection
  3. **UC-MSCs were freeze/thawed prior to infusion; however, PL-MSCs were freshly administered
  4. ***To avoid the patients/participants identity being revealed, age presented as a range and gender as (1/2)